Pharmaceutical Strategy Analysis l Report Store l Pharma Intelligence

Precision Medicine and the Future of Healthcare

Precision medicine is typically associated with the use of therapies that target particular disease-linked genetic mutations, identified via a diagnostic test.

October 14, 2016

Find out more

Trends in Gene Therapy

$2,995.00

Datamonitor Healthcare has carried out a comprehensive analysis of gene therapy products in commercial development worldwide based on information derived from Pharmaprojects.

October 14, 2016

Find out more

R&D Trends 2016

$2,995.00

Over the nine-year period from 2006 to 2014, the Big Pharma, Mid Pharma, and Japan Pharma peer sets collectively spent an annual average of $94bn on R&D of pharmaceuticals, with spending growing at a compound annual growth rate (CAGR) of 6%.

October 17, 2016

Find out more

Immuno-Oncology Deal Trends, 2011–15

$5,000.00

Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated. The Big Pharma and Mid Pharma peer sets are an integral part of development and have been furthering efforts via deal-making.

October 14, 2016

Find out more

Big Pharma Licensing Trends, 2011–15

$5,000.00

Between 2011 and 2015, Big Pharma – a peer set of approximately 16 firms across the world with large R&D and sales organizations, and sales valued at $10bn or more – signed over 1,100 drug-focused deals, growing at a compound annual growth rate of 10%.

October 14, 2016

Find out more

Pharma Externalization Strategies 2016: Externalization is Critical to Pharma Revenue

$2,995.00

Pharmaceutical companies constantly re-assess their pipelines and portfolios to determine the best strategies for their business.

October 17, 2016

Find out more

CER, HEOR, and Value-Based Frameworks in the US

$2,995.00

It is no secret that Americans spend heavily on healthcare – in 2013, US healthcare expenditure totaled nearly $3bn ($9,255 per person) and accounted for 17.4% of gross domestic product.

October 17, 2016

Find out more

Key Trends in BRICMIST Market Access

$2,995.00

Brazil, Russia, India, China, Mexico, Indonesia, South Korea, and Turkey – known collectively as the BRIC/MIST countries – have been a source of welcome growth for a pharmaceutical industry struggling to generate significant gains in its traditional core markets.

October 17, 2016

Find out more

Psoriatic Arthritis: Market Access Pricing & Reimbursement

$2,995.00

Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriatic arthritis market.

October 17, 2016

Find out more

copd-pricing-reimbursement-and-access_160221_10-2016

Chronic Obstructive Pulmonary Disease (COPD): Market Access Pricing & Reimbursement

$7,000.00

Long-acting beta 2 agonist/long-acting muscarinic antagonist (LABA/LAMA) combination inhalers have been gaining traction due to an expanding evidence base for their wider use, and competitive pricing.

October 17, 2016

Find out more

prostate-cancer-pricing-reimbursement-and-access_162106_10-2016

Prostate Cancer: Market Access Pricing & Reimbursement

$2,995.00

The prostate cancer market has become saturated in the metastatic castration-resistant prostate cancer (CRPC) setting; the approval of second-generation antiandrogens, radiotherapies, and chemotherapies has resulted in a great deal of development targeting earlier stages of the disease.

June 1, 2018

Find out more

Multiple Myeloma Pricing, Reimbursement, and Access

$2,995.00

Highlights: The budget impact of multiple myeloma is set to increase While multiple myeloma represents a relatively small patient population in comparison to other cancers, payers are concerned about the rising spend on the indication. New biologic therapies are increasingly gaining label expansions in earlier treatment lines, and with life expectancies improving, patients are requiring […]

March 5, 2019

Find out more

Asthma Pricing, Reimbursement, and Access

$2,995.00

The next wave of key therapies in asthma includes biologics, with interleukin (IL)-5 inhibitors first to reach the market.

October 17, 2016

Find out more

US Healthcare System Overview

$2,995.00

Continued growth in healthcare expenditure and the high number of individuals without health insurance coverage were the key drivers of the passage of the healthcare reform law.

November 2, 2016

Find out more

UK Regulatory Issues

$2,995.00

Recently there have been several new regulatory changes in the UK aimed at reducing the regulatory burden and allowing earlier access to medicines which are seen as a positive development for the pharmaceutical industry.

November 2, 2016

Find out more

Strategy analysis

Precision Medicine and the Future of Healthcare

Trends in Gene Therapy

R&D Trends 2016

Immuno-Oncology Deal Trends, 2011–15

Big Pharma Licensing Trends, 2011–15

Pharma Externalization Strategies 2016: Externalization is Critical to Pharma Revenue

CER, HEOR, and Value-Based Frameworks in the US

Key Trends in BRICMIST Market Access

Psoriatic Arthritis: Market Access Pricing & Reimbursement

Chronic Obstructive Pulmonary Disease (COPD): Market Access Pricing & Reimbursement

Prostate Cancer: Market Access Pricing & Reimbursement

Multiple Myeloma Pricing, Reimbursement, and Access

Asthma Pricing, Reimbursement, and Access

US Healthcare System Overview

UK Regulatory Issues